13年肾下型动脉粥样硬化性穿透性主动脉溃疡腔内修复的技术与临床结局
单中心回顾性观察研究纳入2010至2023年连续治疗的47例肾下型动脉粥样硬化性穿透性主动脉溃疡患者,报告腔内修复后30天、1年、2年及5年的技术与临床结局。初次技术成功42/47(89.4%),二次技术成功46/47(97.9%),5年总生存率82.0%,仅1例(2.1%)PAU相关死亡。作者认为标准腹主动脉双髂动脉EVAR之外需多种替代方案,且腰动脉和/或肠系膜下动脉栓塞可能预防2型内漏。
要点
- 47例肾下型PAU腔内修复,初次技术成功89.4%,二次技术成功97.9%。
- 5年总生存率82.0%,PAU相关死亡1例(2.1%)。
- 术前或术中腰动脉和/或肠系膜下动脉栓塞患者随访中均未发生2型内漏。
核心结论
- 肾下型PAU腔内修复需要标准腹主动脉双髂动脉EVAR之外的多种替代方案。
- 为确定这些病例的最佳管理策略,需要进一步研究。
- 腹部PAU疾病中的2型内漏似乎可通过腰动脉和/或肠系膜下动脉栓塞预防。
研究设计与样本
- 单中心、回顾性观察研究,连续纳入2010年至2023年因动脉粥样硬化性肾下型PAU接受治疗的全部患者。
- 共纳入47例患者,其中女性8例(17.0%),中位年龄75.7岁(IQR:70.2-81.0)。
- 中位最大主动脉直径为39.7 mm(IQR:33.6-45.2)。
- 研究注册于德国临床试验注册中心(DRKS00028794)。
主要发现
- 初次技术成功42/47(89.4%),二次技术成功46/47(97.9%)。
- 标准腹主动脉双髂动脉EVAR为最常见术式,25例(53.2%);腹主动脉单髂动脉支架系统5例(10.6%);其余17例(36.2%)采用腹主动脉-腹主动脉管状支架配置。
- 中位临床随访5.1年(IQR:1.9-8.1),中位影像随访1.5年(IQR:0.4-5.0)。
- 30天、1年、2年、5年总生存率分别为100%(CI:100%-100%)、95.4%(CI:89.4%-100%)、87.9%(CI:78.4%-98.4%)、82.0%(CI:70.7%-95.2%)。
- PAU相关死亡1例(2.1%)。
临床怎么用
- 作者认为,肾下型PAU腔内修复需要标准腹主动脉双髂动脉EVAR之外的多种替代方案。
- 作者认为,腹部PAU疾病中的2型内漏似乎可通过腰动脉和/或肠系膜下动脉栓塞预防。
- 作者指出,为确定这些病例的最佳管理策略,需要进一步研究。
局限性
- 原文在结论中提出需要进一步研究以确定最佳管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To report the technical and clinical outcomes of endovascular repair of all infrarenal, penetrating aortic ulcers (PAUs) that were treated at a single institution over a 13-year period. METHODS: This is a single-center, retrospective observational study. All patients consecutively treated for atherosclerotic, infrarenal PAU were included between 2010 and 2023. Outcomes were technical success, overall survival, PAU-related death, freedom from secondary rupture, freedom from secondary interventions, freedom from aortic expansion >5 mm, freedom from type 1 and type 3 endoleak (EL), and freedom from stent graft migration, each at 30 days, 1 year, 2 years, and 5 years of follow-up. The study was registered at the German Clinical Trials Register (DRKS00028794). RESULTS: Forty-seven patients were included (8 female patients, 17.0%) with a median age of 75.7 years (interquartile range (IQR): 70.2-81.0). The median maximum aortic diameter was 39.7 mm (IQR: 33.6-45.2). Overall, primary and secondary technical success was achieved in 42 of 47 (89.4%) and 46 of 47 patients (97.9%). Standard aortobiiliac endovascular aneurysm repair (EVAR) was the most frequent procedure in 25 patients (53.2%). An aortomonoiliac stent graft system was used in 5 patients (10.6%). The remaining 17 patients (36.2%) were treated using an aorto-aortic tube stent graft configuration. The median clinical follow-up was 5.1 years (IQR: 1.9-8.1) with a median imaging follow-up of 1.5 years (IQR: 0.4-5.0). Overall survival at 30 days, 1, 2, and 5 years of follow up was estimated at 100% (confidence interval (CI), 100%-100%), 95.4% (CI, 89.4%-100%), 87.9% (CI, 78.4%-98.4%), and 82.0% (70.7%-95.2%), respectively. There was 1 PAU-related death (2.1%). Freedom from secondary intervention at 30 days, 1, 2, and 5 years of follow-up was 93.6% (CI, 86.9-100%), 89.2% (CI, 80.6-98.6%), 81.5% (CI, 70.7-94.0%), and 75.2% (CI, 62.8-90.2%), respectively. No patient who underwent either preoperative (n = 1) or intraoperative embolization (N = 7) of lumbar arteries (LAs) and/or the inferior mesenteric artery (IMA) demonstrated type 2 EL during follow-up. CONCLUSION: A variety of alternatives to standard aortobiiliac EVAR are required for endovascular PAU repair. To identify the optimal management strategy in these cases further studies are needed. Type 2 EL in abdominal PAU disease appears to be preventable by LA and/or IMA embolization.
引用
- Hatzl J, Fiering J, Barb A, et al. Technical and Clinical Outcomes of 13 years of Endovascular Repair of Infrarenal, Atherosclerotic, Penetrating Aortic Ulcers. Ann Vasc Surg. 2025. PMID: 39880281. doi:10.1016/j.avsg.2025.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。